



MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH
WEEKLY INFLUENZA UPDATE
January 30, 2015

All data in this report are preliminary and subject to change as more information is received.


Sentinel Provider Surveillance: Influenza-like illness activity

Week 3 Activity¹ (representing geographic distribution): Widespread

Week 3 ILI Activity² (representing intensity of ILI activity): 9 (High)

Provider offices across the US report the amount of influenza-like illness (ILI) they see in their patients each week during regular flu season. These outpatient providers' offices, which include doctors' offices, school health services, and community health centers, are called 'sentinel sites.' Here we present Massachusetts sentinel site data. Please note that the data represent not only confirmed influenza cases, but also those just with ILI, which may be caused by other viruses. ILI is defined as fever above 100.0¹ in addition to either cough or sore throat. ILI is a marker of influenza and is used throughout the regular influenza season to monitor influenza since most people are not tested for influenza. Figure 1 shows that ILI continues to increase, consistent with expected activity during this time of year. For more information, see CDC's influenza surveillance website at www.cdc.gov/flu/weekly/fluactivitysurv.htm.

Figure 1: Percentage of ILI visits reported by sentinel provider sites



*Influenza-like illness (ILI, defined by fever >100F and cough and/or sore throat), as reported by Massachusetts sentinel surveillance sites

¹ CDC activity indicator – indicates how widespread influenza activity level is in the state.

² CDC ILI activity indicator – more quantitative indicator of the level of ILI activity across the state.

Table 1 below shows a geographical distribution of reported ILI in Massachusetts. Table 1 shows that sentinel sites in six of seven regions of the state are experiencing elevated ILI activity.

Table 1: Percent ILI reported weekly by Massachusetts sentinel sites


	Regional Baseline % ILI*	2014-2015			2013-2014		
		% ILI	Report. Sites	Total enroll.	% ILI	Report. Sites	Total enroll.
Boston	1.04	2.89	3	6	1.16	6	6
Central	1.55	1.40	9	11	1.61	9	12
Inner Metro Boston	0.89	3.64	11	12	2.05	10	13
Northeast	0.93	5.38	9	9	1.97	9	11
Outer Metro Boston	1.65	4.01	4	5	2.50	5	5
Southeast	0.41	0.88	3	6	1.28	6	6
West	0.94	2.23	4	7	1.33	7	7

*Regional baseline % ILI is calculated weekly using reporting providers' baseline % ILI estimates.

Influenza-Associated Hospitalizations

In 2010, MDPH began to request voluntary reporting of all laboratory-confirmed influenza hospitalizations from hospitals in Massachusetts. As many as 50 acute care hospitals from across the state report these data to MDPH on a weekly basis during flu season. The graph below shows the number of laboratory-confirmed hospitalizations per 1,000 licensed beds represented by reporting hospitals for the current season and two previous seasons.

Figure 2: Massachusetts laboratory-confirmed influenza hospitalizations



Laboratory testing for influenza

Laboratories in Massachusetts report all positive influenza laboratory tests to MDPH, including viral culture, polymerase chain reaction (PCR) and rapid influenza diagnostic tests. Because the majority of cases are not tested, the number of 'confirmed' cases does not reflect the overall incidence of influenza; however, this information is essential to track the types of influenza circulating in Massachusetts and can be a useful indicator of the presence and distribution of influenza in the state. Figure 3 illustrates the number of laboratory confirmed cases in Massachusetts by week, shown along with Massachusetts ILI. Table 2 reflects the number of laboratory-confirmed influenza cases by region and influenza type.




Table 2: Laboratory-confirmed Influenza by Region – 2014-2015 and 2013-2014 Influenza Seasons

Region	2014-2015						2013-2014					
	A		B		Untyped		A		B		Untyped	
	Week	YTD	Week	YTD	Week	YTD	Week	YTD	Week	YTD	Week	YTD
Boston	292	865	8	50	7	49	53	291	2	17	0	1
Central	247	986	19	99	25	85	58	240	15	86	8	35
Inner Metro Boston	370	1632	7	81	9	88	72	380	4	12	0	4
Northeast	686	2557	17	141	56	181	119	622	27	190	9	59
Outer Metro Boston	275	1497	4	77	16	111	42	264	2	8	0	1
Southeast	591	2223	19	106	28	166	107	458	6	28	0	3
Unknown	191	666	8	42	7	21	27	142	1	12	0	0
West	128	656	4	31	1	30	59	348	0	2	0	1
Total	2,780	11,082	86	627	149	731	537	2,745	57	355	17	104

Testing at the Hinton State Laboratory Institute

As part of a more comprehensive respiratory surveillance initiative, MDPH’s Bureau of Laboratory Sciences (MDPH-BLS) performs testing to confirm typing and subtyping of circulating influenza viruses followed by testing of influenza-negative samples for the evidence of adenovirus, respiratory syncytial virus (RSV) A/B, parainfluenza virus (PIV) types 1-4 , coronavirus (HCoV) HKU1, OC43, NL63, 229E, human metapneumovirus (HMPV), and rhinovirus/enterovirus (RHV/ENT) using a multiplex PCR respiratory viral panel. Samples are submitted by ~60 outpatient healthcare providers (ILINet) and include early influenza positives, as well as specimens and isolates from clinical hospital diagnostic laboratories across Massachusetts. For the 2014-2015 season, Figure 4 and Tables 3 and 4 summarize virologic surveillance testing conducted by MDPH-BLS beginning MMWR week 40 (week ending October 4, 2014). MDPH-BLS performs influenza surveillance testing year round. For the 2014-2015 season to date, four cases of influenza B, one case of A/2009 H1N1, and 118 cases of A/H3N2 influenza have been confirmed in 223 cases tested.

Figure 4: Influenza positive tests reported to CDC by MDPH-BLS, September 28, 2014 – January 24, 2015




Table 3: Weekly Summary of MDPH-BLS Influenza Surveillance Test Results

2014-2015 Season: Influenza Surveillance									
MA Department of Public Health's Bureau of Laboratory Sciences (MDPH-BLS)									
MMWR Week: (Specimen Collected)	2009 H1N1	seasonal A/H3N2	B	H3N2v	A unsub	No. Flu Pos (%)	Unsat	Total Tested	Total Rec'd
53 (12/28/14- 1/3/2015)	0	12	1	0	0	13(93%)	0	14	14
01 (1/04- 1/10/2015)	0	12	0	0	0	12(75%)	3	16	19
02 (1/11- 1/17/2015)	0	23	1	0	0	24(77%)	5	31	36
03 (1/18- 1/24/2015)	0	37	0	0	0	37(70%)	1	53	54
Prior 4 wk Total	0	84	2	0	0	86(75%)	9	114	123
Cumulative Season total	1	118	4	0	0	123(55%)	23	223	246

All data are subject to change as test results become finalized. The 2014 -2015 influenza season began MMWR 40 (09/28- 10/04/2014).

Table 4: Weekly Summary of MDPH-BLS non-Influenza Respiratory Surveillance Test Results

2014-2015 Season: Influenza Like Illness Surveillance											
MA Department of Public Health's Bureau of Laboratory Sciences (MDPH-BLS)											
MMWR Week: (Specimen Collected)	RSV	RHV/ ENT	PIV	HMPV	HCV	ADV	# Co- Infection	No. Pos (%)	Unsat	Total Tested	Total Rec'd
53 (12/28- 1/03/2015)	0	0	0	0	0	0	0	0(0%)	0	1	1
01 (1/04- 1/10/2015)	0	0	0	0	0	0	0	0(0%)	0	4	4
02 (1/11- 1/17/2015)	0	1	1	2	0	0	0	4(57%)	0	7	7
03 (1/18- 1/24/2015)	1	3	1	1	0	0	2	4(27%)	2	15	17
Prior 4 wk Total	1	4	2	3	0	0	2	8(30%)	2	27	29
Cumulative Season total	2	19	3	3	4	3	3	31(35%)	9	89	98

All data are subject to change as test results become finalized. The 2014 -2015 influenza season began MMWR 40 (09/28- 10/04/2014).

At the start of the 2014-2015 season, the first 10 influenza virus isolates and thereafter 5 representative isolates every two weeks will be sent by MDPH-BLS to a CDC contract laboratory performing National Influenza Virus Surveillance to include antigenic characterization by hemagglutination inhibition (HI), genetic analysis (sequencing) and sensitivity to FDA-approved drugs for identification of resistance. Seven influenza A (H3N2) specimens, one A (2009 H1N1), and one B have been characterized for the 2014-2015 season. The influenza B, A (2009 H1N1), and three of the A (H3N2) specimens were consistent with strains in the 2014-2015 seasonal influenza vaccine. Four A (H3N2) specimens showed evidence of antigenic drift in laboratory (HI) testing at CDC, suggesting a lower likelihood of protection from this year's vaccine.

As samples are received, MDPH-BLS will screen additional samples every two weeks to detect point mutations within the neuraminidase gene of influenza A/H3N2 viruses (E119, R292, and N294) and influenza A/2009 H1N1 viruses (H275 and I223) to assess resistance trends. This information will be reported locally and captured nationally in FluView (<http://www.cdc.gov/flu/weekly/>). There were three influenza A/2009 H1N1 isolates from MA during the 2009-2010 season with a mutation conferring oseltamivir-resistance (H275Y) and none during the following four seasons.

Table 5: DPH-BLS Influenza Antiviral Resistance Screening: 2014-2015 Season

Virus Collection Period: September 28, 2014- ongoing				
	Oseltamivir		Zanamivir	
	Samples Tested	Resistant Viruses, Number (%)	Samples Tested	Resistant Viruses, Number (%)
Influenza A (H3N2) ⁱ	41	0 (0)	24	0 (0)
Influenza A (H1N1)pdm09 ⁱⁱ	0	0 (0)	0	0 (0)

ⁱ Samples tested by pyrosequencing at position E119, R292, and N294 within the neuraminidase (NA) gene.

ⁱⁱ Samples tested by pyrosequencing at position H275 and I223 within the NA gene.

Additional information on national antiviral resistance testing including recommendations for antiviral treatment and chemoprophylaxis of influenza virus infection can be found at <http://www.cdc.gov/flu/weekly/>.